Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red
blood cells (hematocrit), physiological ions and coagulation factors that can contribute to
impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot
study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing
hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative
mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to
evaluate whether retrograde autologous priming and/or mannitol are superior to conventional
priming alone.